Claims for Patent: 9,534,226

Summary for Patent: 9,534,226

Title:	Expression vector system comprising two selection markers
Abstract:	The invention pertains to an expression vector or a combination of at least two expression vectors comprising at least (a) a polynucleotide encoding a product of interest or an insertion site for incorporating a polynucleotide encoding a product of interest; (b) a polynucleotide encoding a first selectable marker (sm I); (c) a polynucleotide encoding a second selectable marker (sm II), which is different from the first selectable marker (sm I), wherein the activity of the selectable marker (sm I) or (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield.
Inventor(s):	Jostock; Thomas (Neuenburg am Rhein, DE), Knopf; Hans-Peter (Schallstadt, DE)
Assignee:	Novartis AG (CH)
Application Number:	13/203,610
Patent Claims:	1. An expression vector or a combination of at least two expression vectors comprising at least (a) a polynucleotide encoding a product of interest or an insertion site for incorporating a polynucleotide encoding a product of interest; (b) a polynucleotide encoding a first selectable marker (sm I); and (c) a polynucleotide encoding a second selectable marker (sm II); wherein the activity of the selectable marker (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism, and wherein the first selectable marker (sm I) is a functional membrane-bound folate receptor and the second selectable marker (sm II) is DHFR. 2. The expression vector or combination of at least two expression vectors according to claim 1, a) wherein the second selectable marker (sm II) is wildtype DHFR; and/or b) wherein the second selectable marker is a DHFR comprising an intron or fragment thereof at the 3' end of the open reading frame of the DHFR gene that is less sensitive to MTX than the wildtype DHFR enzyme or the DHFR enzyme endogenously expressed by the host cell; or c) wherein the second selectable marker is a DHFR comprising an intron or fragment thereof at the 3' end of the open reading frame of the DHFR gene that is less sensitive to MTX than both the wildtype DHFR enzyme and the DHFR enzyme endogenously expressed by the host cell. 3. The expression vector or combination of at least two expression vectors according to claim 1, wherein the polynucleotide encoding the product of interest is comprised in an expression cassette which comprises a) the polynucleotide encoding the product of interest; b) at least one stop codon downstream of the polynucleotide encoding the product of interest; and c) a polynucleotide downstream of the stop codon encoding a membrane anchor and/or a signal for a membrane anchor. 4. The expression vector or combination of at least two expression vectors according to claim 2, wherein the polynucleotide encoding the product of interest is comprised in an expression cassette which comprises a) the polynucleotide encoding the product of interest; b) at least one stop codon downstream of the polynucleotide encoding the product of interest; and c) a polynucleotide downstream of the stop codon encoding a membrane anchor and/or a signal for a membrane anchor. 5. The expression vector or combination of at least two expression vectors according to claim 1, wherein the functional membrane-bound folate receptor has or comprises an amino acid sequence as set forth in SEQ ID NO 1, 2 or 3. 6. A host cell comprising (a) an introduced polynucleotide encoding a product of interest; (b) an introduced polynucleotide encoding a first selectable marker (sm I); and (c) an introduced polynucleotide encoding a second selectable marker (sm II); wherein the activity of the selectable marker (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism, and wherein the first selectable marker (sm I) is a functional membrane-bound folate receptor and the second selectable marker (sm II) is DHFR. 7. The host cell according to claim 6, wherein said cell is a CHO cell, a DHFR.sup.+ (plus) cell, or a CHO cell that is DHFR.sup.+ (plus) cell. 8. The host cell according to claim 6, wherein the host cell is a DHFR.sup.+ (plus) cell and the second selectable marker (sm II) is a DHFR comprising an intron or fragment thereof at the 3' end of the open reading frame of the DHFR gene that is less sensitive to MTX than either the wildtype DHFR enzyme or the DHFR enzyme endogenously expressed by the host; or wherein said host cell is a DHFR.sup.+ (plus) cell and the second selectable marker (sm II) is a DHFR comprising an intron or fragment thereof at the 3' end of the open reading frame of the DHFR gene that is less sensitive to MTX than both the wildtype DHFR enzyme or the DHFR enzyme endogenously expressed by the host. 9. The host cell according to claim 6, wherein the functional membrane-bound folate receptor has or comprises an amino acid sequence as set forth in SEQ ID NO 1, 2 or 3.

Details for Patent 9,534,226

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-02-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-02-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-02-27